CAM
SEEL

Connacht Asset Management’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Connacht Asset Management’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-60
Closed -$194K – 182
2022
Q1 		$194K Sell
60
-70
-54% -$301K 0.1% 118
2021
Q4 		$813K Sell
130
-11
-8% -$84.5K 0.79% 45
2021
Q3 		$1.3M Buy
141
+33
+31% +$284K 0.84% 41
2021
Q2 		$1.09M Buy
+108
New +$1.77M 0.47% 68

Other funds holding SEEL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Connacht Asset Management's SEEL Position: Q2 2022 in Review

Connacht Asset Management sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q2 2022, closing a stake of 60 shares — an estimated $194K sold.

Connacht Asset Management first reported a position in SEEL in Q2 2021 and held it in 4 quarters. The position peaked at $1.3M in Q3 2021. 65 funds tracked by Wall St. Rank hold SEEL as of Q2 2022.

  • Connacht Asset Management reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Connacht Asset Management sold 60 Seelos Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $194K.
  • Connacht Asset Management first reported a position in Seelos Therapeutics, Inc. Common Stock in Q2 2021 and held it in 4 quarters.
  • Connacht Asset Management's Seelos Therapeutics, Inc. Common Stock position peaked at $1.3M in Q3 2021.
  • 65 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Connacht Asset Management's 13F filing for Q2 2022, filed 15 Aug 2022.